medroxyprogesterone has been researched along with Thrombopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emrich, LJ; Lele, SB; Patsner, B; Piver, MS | 1 |
2 trial(s) available for medroxyprogesterone and Thrombopenia
| Article | Year |
|---|---|
Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Female; Humans; Leukopenia; Lung Neoplasms; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Neoplasms; Random Allocation; Rectal Neoplasms; Thrombocytopenia; Time Factors | 1986 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans; Medroxyprogesterone; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Random Allocation; Tamoxifen; Thrombocytopenia; Uterine Neoplasms | 1986 |